Veriheal

DECEMBER 28, 2021

Over the last few decades, the cannabis plant and its many components have been the focal point of research and stiff debate. D espite the Drug Enforcement Agency’s (DEA) announcement in May that it would soon start reviewing grower applications for research purposes, cannabis research continues to be tightly restricted.

Research and Development 98

Research and Development Chronic Pain Treatment Medicine 98

Cannabis Law Report

JULY 27, 2021

The initiative is part of Project Change Lives; Clever Leaves’ $25M product pledge to aid cannabis research in the U.S. The collaboration represents the Company’s first funded study with a research institution in the United States. organization to help advance scientific research into the potential medical benefits of cannabinoids.

Pharmaceutical 76

Pharmaceutical Research and Development Sativa Extraction 76

Veriheal

JUNE 29, 2021

Did we ever stop to think that if we could legally utilize the plants in the first place that perhaps we wouldn’t develop terminal illnesses at such a high rate? The lawsuit came after the DEA denied their application to utilize a synthetic form of psilocybin under the RTT laws. Introducing the Right to Try Act.

Therapy 64

Therapy DEA Patients Clinical Trials 64

Canna Law Blog

MARCH 4, 2020

People are increasingly using ketamine for ailments that resist treatment through traditional pharmaceutical drugs. See, for example, this comprehensive ketamine infusion therapy checklist developed by the American Association of Nurse Anesthetists.

Therapy 106

Therapy Legalization Chronic Pain DEA 106

CannaMD

AUGUST 8, 2020

Researchers believe cannabis contains over 100 unique chemical compounds! Drugs, substances, and certain chemicals used to make drugs are classified into five categories (known as schedules ) depending on the Department of Drug Enforcement Agency (DEA)’s definition of the drug’s acceptable medical use and abuse/dependency potential.

CBD 105

CBD DEA Research and Development Hemp 105

SpeedWeed

JULY 23, 2021

Denver is expanding Alzheimer’s research through the efforts of local company MedPharm. . The company plans to move forward with research efforts through a special Schedule I Researcher Licenses given specifically to the company by the Drug Enforcement Administration. Denver Company Moves Forward with Research License .

Clinical Trials 52

Clinical Trials Research and Development DEA Cannabinoids 52

Veriheal

JUNE 30, 2023

A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Veriheal

DECEMBER 27, 2022

Let’s dive into what the research says about these promising new findings and how they might advance the field of psychedelic research. Some research suggests that these substances could be used to treat mental health conditions like depression and anxiety. The subjective nature of self-reported data can plague research.

Research and Development 102

Research and Development Therapy Consumption DEA 102

Veriheal

AUGUST 24, 2022

If passed, the Department of Regulatory Agencies would be required to develop rules that would allow for therapeutic psychedelic programs at licensed healing centers for adults to receive psychedelic treatments by a trained facilitator. Research and Testimonials Point to Psychedelics’ Therapeutic Benefits.

Legalization 111

Legalization Decriminalization Medicine Research and Development 111

Cannabis Law Report

JULY 1, 2021

On June 30th, the Petrie-Flom Center announced the launch of a three-year research initiative , the Project on Psychedelics Law and Regulation (POPLAR) , which is supported by a generous grant from the Saisei Foundation. POPLAR will publish original law and policy research. What barriers exist to conducting psychedelics research?

Law 81

Law Research and Development Therapy DEA 81

Cannabis Law Report

JULY 9, 2021

Not only are more and more jurisdictions decriminalizing the use of psychedelics for recreational purposes, but it appears that psychedelic substances are the new horizon for the treatment of severe psychological disorders and other ailments. Psychedelic therapy is not a fringe phenomenon.

Law 81

Law Therapy Clinical Trials Research and Development 81

Veriheal

AUGUST 31, 2020

We are humbled to introduce you to them and their exceptional ideas, ranging from community grassroots mental health efforts designed to empower historically vulnerable communities of color, to research plans for identifying strain specific genetics. Veriheal’s Innovation in Cannabis Scholarship 2020 Winners . Nishtha Tripathi.

Research and Development 119

Research and Development Education Agriculture Patients 119

MedicalJane

JUNE 29, 2018

On June 26, 2018, the FDA granted approval of Epidiolex, a cannabidiol (CBD) oral solution, to GW Research Ltd (GW). The new drug is indicated for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. branch of Aphria, Inc.,

Clinical Trials 53

Clinical Trials CBD DEA Research and Development 53

Cannabis Law Report

AUGUST 18, 2022

Smith , a partner with the firm and co-leader of the firm’s Life Sciences & Health Effects Team, will lead the practice, bringing together scientist-attorneys and experienced litigators to support clients that are driving innovation in mental health treatments. BUFFALO, N.Y. , Aug. Phillips Lytle Special Counsel Kyle W.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

Cannabis Law Report

FEBRUARY 10, 2022

Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). By Allison Campbell.

DEA 52

DEA Clinical Trials Policy Research and Development 52

Cannabis Law Report

OCTOBER 5, 2021

“This shows that combination of psilocybin and music has a strong emotional effect, and we believe that this will be important for the therapeutic application of psychedelics if they are approved for clinical use,” said lead researcher Dea Siggaard Stenbæk , Associate Professor University of Copenhagen.

Clinical Trials 52

Clinical Trials Research and Development DEA Therapy 52

Cannabis Law Report

APRIL 8, 2022

as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. Rick Doblin founded MAPS as an official 501(c)(3) non-profit research organization on April 8, 1986. Later that year, Doblin sued the DEA for the first time.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Veriheal

JUNE 24, 2021

health official reportedly slammed “ongoing federal restrictions that are inhibiting research into marijuana”. The Senator stated that the NIH has been reporting on “potentially promising peer-reviewed clinical research” and asked for an update on how the NIH was planning to proceed and navigate issues. .

Research and Development 52

Research and Development Clinical Trials Treatment Access 52

SpeedWeed

AUGUST 11, 2021

According to Dr. Sue Sisley, President of the Scottsdale Research Institute and longtime cannabis researcher, this new study is sorely needed in the community. Veterans are demanding objective cannabis drug development research, and the state of Michigan is fulfilling our collective obligation to our beloved Veteran community.”.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical DEA 52

The Cannigma

MAY 1, 2023

Named because it is the result of the joining two different chemical types – a ketone and an amine, ketamine was developed in 1962 as an alternative dissociative anesthetic drug to the potently hallucinogenic phencyclidine, known more commonly as PCP. It was becoming clear that another class of anesthetics was needed.

Blood Pressure 80

Blood Pressure Chronic Pain Research and Development Clinical Trials 80

Cannabis Law Report

SEPTEMBER 1, 2021

While there has been increasing attention and interest in this issue on Capitol Hill, in the near term the federal tax treatment of cannabis-related business remains fraught with risks. 12] Ultimately, only Congress can amend the CSA itself to remove, or otherwise reform the treatment of cannabis under federal law. August 30, 2021.

Policy 100

Policy Cannabis Law Treatment 100

Medicinal Genomics

JULY 13, 2023

So here are just a dozen new developments, breakthroughs, and aha moments from this year’s summit that might just convince you to circle CannMed 24 on your calendar right now. the VP of Research & Development at Biopharmaceutical Research Company, Inc., But if you weren’t able to be there, you wouldn’t know that.

Research and Development 52

Research and Development Cannabinoids Medicine DEA 52

Cannabis Law Report

JULY 12, 2019

By: James Holley, Molecular Biologist, Scientific Officer, Mike Robinson, Co-founder, Research Institute, and Dr. David Ostrow, M.D., Research Director. International Cannabinoid Cancer Research Institute (Draft 5). This report (abstract below) asks if Epidiolex is as efficient a drug as the manufacturer believes it to be.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73

United Patients Group

APRIL 3, 2023

Epidiolex, an FDA-approved medication containing CBD (cannabidiol), has been listed as Schedule 5 by the DEA since June 25th, 2019. The doctor who writes the prescription must be licensed and has to write it for a specific patient, as opposed to prescribing general instructions for treatment. Cannabis is a schedule 1 substance.

DEA 52

DEA Patients Conditions Cannabis 52

Cannabis Law Report

APRIL 13, 2022

North American Industry Leader in Psychedelic Therapy and Research. Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory. Watch Video: The Press Release. NEWS PROVIDED BY. Numinus Wellness Inc. .

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Cannabis Law Report

AUGUST 12, 2022

Obtaining DEA License to Grow Psilocybin Mushrooms. This panel would explore topics such as the ethical implications of psychedelic-based drug development and patenting, as well as the debate over producing and marketing natural versus synthetic psychedelics. The discussion would be moderated by Forbes’s Lindsey Bartlett.

Research and Development 52

Research and Development Topical Events Policy 52

Weedistry

MARCH 7, 2019

Marijuana Fights Cancer and Helps Manage Side Effects, Researchers Find. She had been screening brain cancer cells because they grow faster than normal cell lines and thus are useful for research purposes. The ID -1 gene is active during human embryonic development, after which it turns off and stays off.

THC 40

THC CBD Clinical Trials Research and Development 40

Cannabis Law Report

JUNE 15, 2021

. – Today, ahead of the 50th anniversary—on June 17—of when President Richard Nixon declared the “war on drugs,” Representatives Bonnie Watson Coleman (D-NJ) and Cori Bush (D-MO) unveiled the Drug Policy Reform Act (DPRA), alongside the Drug Policy Alliance, which has been a strategic partner on the development of the legislation.

Decriminalization 60

Decriminalization Policy Research and Development Data 60

The Joint Blog

JUNE 4, 2021

Believe it or not, you actually need a license to do meaningful research on marijuana due to the fact that the United States Drug Enforcement Agency (DEA) has limited its access. The DEA feels that marijuana, being a schedule I drug, could be misused like other drugs within that category and could be dangerous. Cancer pain.

Conditions 32

Conditions Chronic Pain Marijuana Research and Development 32

Cannabis Law Report

SEPTEMBER 23, 2019

Marijuana and Cannabinoids: Health, Research and Regulatory Considerations (Position Paper). The AAFP urges its members to be involved in the diagnosis, treatment, and prevention of substance use, as well as secondary diseases impacted or caused by use. This process should also ensure appropriate funding allocated for this research.

Cannabinoids 40

Cannabinoids Marijuana Research and Development Access 40

The Cannigma

JULY 3, 2023

The clues we have from existing literature indicate that while it’s probably safe, there’s insufficient clinical research to confirm or dispel it. Happily, the body of research into cannabis and psychedelics (including MDMA) is expanding fast, and it’s likely that better data on their interactions will become available in the near future.

Research and Development 46

Research and Development Environment THC Microdosing 46

SpeedWeed

MARCH 5, 2021

One, they have been determined by the US Food and Drug Administration to be clinically safe and effective treatments for a specific medical condition. Two, they are federally classified by DEA and HHS as Schedule II, III, IV or V substances. Rescheduling cannabis will not necessarily facilitate clinical research.

Business 52

Business Policy Clinical Trials Research and Development 52

The Cannigma

FEBRUARY 16, 2022

To hear more about Steven’s research, what he hopes it will lead to, his predictions for the future of cannabis, how he is helping those most harmed by the war on drugs, and how you can help too, tune in today! SP: Yeah, so I guess right now, with my research, I am actually looking to create a catalog of trichomes. SP: Say that again.

Trichome 73

Trichome Wellness and Beauty Cannabinoids Cannabis 73

Cannabis Law Report

APRIL 14, 2022

Although research is still underway, the effects of both short- and long-term exposure to pesticides by consuming (i.e., pursuant to Drug Enforcement Agency (DEA) or state-level programs). by eating or smoking cannabis) are unknown.

Environment 52

Environment Agriculture Compliance Compliance 52

Canna Law Blog

MAY 7, 2020

At the same time, because of the federal illegality of cannabis, the federal government has routinely denied third party requests for further research in regards to its potential medical benefits, among other health and safety impacts. These cannabis products are used by researchers in the U.S.

DEA 96

DEA Research and Development Cultivation Supply Chain 96

Cannabis Law Report

MAY 29, 2022

Earlier this month, Senators Brian Schatz (D-HI) and Cory Booker (D-NJ) sent a letter to the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) urging both agencies to advance research on the therapeutic effects of psychedelic drugs. [1] Recent Regulatory Developments. Challenges.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

The Cannigma

MAY 15, 2023

Because ketamine promotes neuroplasticity, or in other words helps “rewire” the brain,” research shows that it can help stop the repetitive negative thoughts and behaviors that are at the core of many mental health conditions. Patients may want to seek assistance from a certified professional prior to embarking on treatment.

Therapy 78

Therapy Access Blood Pressure Treatment 78